Sutro Biopharma, Inc. (S09.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
As of 09:15AM CET. Market open.
| Previous Close | 6.55 |
| Open | 6.55 |
| Bid | 6.45 x 0 |
| Ask | 6.70 x 0 |
| Day's Range | 6.55 - 6.55 |
| 52 Week Range | 3.20 - 9.25 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 399.253M |
| Beta (5Y Monthly) | 0.93 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.35 |
| Earnings Date | Mar 06, 2023 - Mar 13, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 32.71 |
- Simply Wall St.
Are Investors Undervaluing Sutro Biopharma, Inc. (NASDAQ:STRO) By 46%?
In this article we are going to estimate the intrinsic value of Sutro Biopharma, Inc. ( NASDAQ:STRO ) by estimating the...
- GlobeNewswire
Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer
- Results from the STRO-002 (luvelta) Phase 1 dose-expansion study demonstrate that FolRα-selected patients experienced meaningful clinical benefit, with 43.8% ORR, median DOR of 5.4 months, and median PFS of 6.6 months at the higher starting dose of 5.2mg/kg - - Meaningful clinical benefit was observed in FolRα-selected patients, defined as TPS>25%, which is potentially 80% of the advanced ovarian cancer patient population - - Safety profile is generally consistent with prior data with asymptom
- Simply Wall St.
With 74% ownership of the shares, Sutro Biopharma, Inc. (NASDAQ:STRO) is heavily dominated by institutional owners
If you want to know who really controls Sutro Biopharma, Inc. ( NASDAQ:STRO ), then you'll have to look at the makeup...
© 2023 Yahoo. All rights reserved.
